Transdermal delivery of AT1 receptor antagonists reduce blood pressure and reveal a vasodilatory effect on kidney blood vessels

Current Molecular Pharmacology

Volumn 11, Issue 3, 2018, Pages 226-236

  Michalatou, Michaila ^a,b   Androutsou, Maria Eleni ^b   Antonopoulos, Markos ^c   Vlahakos, Demetrios V ^d   Agelis, George ^b   Zulli, Anthony ^e   Qaradakhi, Tawar ^e   Mikkelsen, Kathleen ^e   Apostolopoulos, Vasso ^e   Matsoukas, John ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b Eldrug   (Greece)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ATHENS   (Greece)

^e VICTORIA UNIVERSITY   (Australia)

Author keywords

Alamandine; Anti hypertensive drug delivery; Blood pressure; Hypertension; Losartan; Skin; Skin patch; Valsartan

Indexed keywords

DIETHYLENE GLYCOL MONOETHYL ETHER; DIMETHYL SULFOXIDE; LOSARTAN POTASSIUM; MYRISTIC ACID ISOPROPYL ESTER; PROPYLENE GLYCOL; VALSARTAN; ALAMANDINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; LOSARTAN; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY BLOOD VESSEL; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEAN ARTERIAL PRESSURE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY; TREATMENT RESPONSE; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS; VASODILATATION; ANIMAL; BLOOD PRESSURE; BLOOD VESSEL; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECT; KIDNEY; LEPORIDAE; MALE; METABOLISM; PHYSIOLOGY; REPRODUCIBILITY; SKIN ABSORPTION; VASCULARIZATION; WISTAR RAT;

ADMINISTRATION, CUTANEOUS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; HUMANS; KIDNEY; LOSARTAN; MALE; OLIGOPEPTIDES; RABBITS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; REPRODUCIBILITY OF RESULTS; SKIN ABSORPTION; VALSARTAN; VASODILATION;

EID: 85049658335     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211666180419152036     Document Type: Article

References (62)

1. Martin del Valle, E.; Galan, M.; Carbonell, R. Drug Delivery Technologies: The way forward in the new decade. Ind. Eng. Chem. Res., 2009, 48, 2475-2486.
2. Yan, K.S.; Yan, T.X.; Guo, H.; Li, J.Z.; Wei, L.L.; Wang, C.; Nie, S.F.; Pan, W.S. Evaluation of transdermal permeability of pentoxifylline gel: in vitro skin permeation and in vivo microdialysis using Wistar rats. Drug Disc. Ther., 2007, 1, 78-83.
3. Paudel, K.S.; Milewski, M.; Swadley, C.L.; Brogden, N.K.; Ghosh, P.; Stinchcomb, A.L. Challenges and opportunities in dermal/transdermal delivery. Ther. Deliv., 2010, 1, 109-131.
4. Walczak, A.; Siger, M.; Ciach, A.; Szczepanik, M.; Selmaj, K. Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol., 2013, 70, 1105-1109.
5. Amit, A.; Shubhangi, D.; Ajazuddin, D.; Tapan, K.; Swarnlata, S.; Shailendra, S.; Dulal, K. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J. Con. Rel., 2012, 164, 26-40.
6. Sheth, N.; Mistry, R. Formulation and evaluation of transdermal patches and to study permeation enhancement of eugenol. J. Appl. Pharm. Sci., 2011, 3, 96-101.
7. Keleb, E.; Sharma, R.; Mosa, E.; Aljahwi, A. Transdermal Drug Delivery System – Design and Evaluation. Int J. Advances Pharm Sci 2010, 1, 201-211.
8. Nishida, N.; Taniyama, K.; Sawabe, T.; Manome, Y. Development and evaluation of a monolithic drug-in-adhesive patch for valsartan. Int. J. Pharm., 2010, 402, 103-109.
9. Vijayan, V.; Sumanth, M.; Suman, L.; Vinay, T.; Srinivasrao, D.; Kumar, K. Development and Physiochemical, in vitro Evaluation of Antihypertensive Transdermal Patches. J. Pharm. Sci. Res., 2010, 2, 171-177.
10. Rizwan, M.; Aqil, M.; Ahad, A.; Sultana, Y.; Ali, M. Transdermal Delivery of Valsartan: I. Effect of various terpenes. Drug Dev. Ind. Pharm., 2008, 34, 618-626.
11. Sinha, V.; Kaur, M. Permeation Enhancers for Transdermal Drug Delivery. Drug Dev. Ind. Pharm., 2000, 26, 1131-1140.
12. Patel, H.; Trivedi, D.; Bhandari, A.; Shah, D. Penetration enhancers for transdermal drug delivery system: A review. J. Pharm. Cosm., 2011, 2, 67-80.
13. Williams, A. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice. Royal Pharmaceutical Press, Great Britain, 2003, 87-95.
14. Mura, P.; Faucci, M.T.; Bramanti, G.; Corti, P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci., 2000, 9, 365-372.
15. Muller, P.; Imhof, P.R.; Burkart, F.; Chu, L.C.; Gerardin, A. Human pharmacological studies of a new transdermal system containing nitroglycerin. Eur. J. Cclin. Pharmacol., 1982, 2, 473-480.
16. Parker, J.O.; Amies, M.H.; Hawkinson, R.W.; Heilman, J.M.; Hougham, A.J.; Vollmer, M.C.; Wilson, R.R. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation, 1995, 91, 1368-1374.
17. Kumagai, Y. Strategies against high blood pressure in the early morning. Clin. Exp. Hypertens., 2004, 262, 107-118.
18. Saydam, M.; Takka, S. Bioavailability File: Valsartan. J. Pharm. Sci., 2007, 32, 185-196.
19. Jain, P.; Banga, A.K. Induction and inhibition of crystallization in drug-in-adhesive-type transdermal patches. Pharm. Res., 2013, 30, 562-571.
20. Agelis, G.; Kelaidonis, K.; Resvani, A.; Kalavrizioti, D.; Androutsou, M.E.; Plotas, P.; Vlahakos, D.; Koukoulitsa, C.; Tselios, T.; Mavromoustakos, T.; Matsoukas, J. Facile and efficient syntheses of a series of N-benzyl and N-biphenylmethyl substituted imidazole derivatives based on (E)-urocanic acid, as angiotensin II AT1 receptor blockers. Molecules, 2013, 18, 7510-7532.
21. Agelis, G.; Resvani, A.; Durdagi, S.; Spyridaki, K.; Tumova, T.; Slaninova, J.; Giannopoulos, P.; Vlahakos, D.; Liapakis, G.; Mavromoustakos, T.; Matsoukas, J. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur. J. Med. Chem., 2012, 55, 358-374.
22. Agelis, G.; Resvani, A.; Koukoulitsa, C.; Tumova, T.; Slaninova, J.; Kalavrizioti, D.; Spyridaki, K.; Afantitis, A.; Melagraki, G.; Siafaka, A.; Gkini, E.; Megariotis, G.; Grdadolnik, S.G.; Papadopoulos, M.G.; Vlahakos, D.; Maragoudakis, M.; Liapakis, G.; Mavromoustakos, T.; Matsoukas, J. Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bissubstituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur. J. Med. Chem.,2013, 62, 352-370.
23. Agelis, G.; Resvani, A.; Ntountaniotis, D.; Chatzigeorgiou, P.; Koukoulitsa, C.; Androutsou, M.E.; Plotas, P.; Matsoukas, J.; Mavromoustakos, T.; Cendak, T.; Godec, T.U.; Mali, G. Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices. Biochimica et biophysica acta, 2013, 1828, 1846-1855.
24. Atlas, S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Managed Care Pharm: JMCP, 2007, 13, 9-20.
25. Agelis, G.; Resvani, A.; Matsoukas, M.T.; Tselios, T.; Kelaidonis, K.; Kalavrizioti, D.; Vlahakos, D.; Matsoukas, J. Towards nonpeptide ANG II AT1 receptor antagonists based on urocanic acid: rational design, synthesis and biological evaluation. Amino Acids, 2011, 40, 411-420.
26. Roumelioti, P.; Tselios, T.; Alexopoulos, K.; Mavromoustakos, T.; Kolocouris, A.; Moore, G.J.; Matsoukas, J.M. Structural comparison between type I and type II antagonists: possible implications in the drug design of AT1 antagonists. Bioorg Med Chem Lett., 2000, 10, 755-758.
27. Mavromoustakos, T.; Apostolopoulos, V.; Matsoukas, J. Antihypertensive drugs that act on Renin-Angiotensin System with emphasis in AT(1) antagonists. Mini Rev Med Chem., 2001, 1, 207-217.
28. Naik, P.; Murumkar, P.; Giridhar, R.; Yadav, M.R. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. Bioorg. Med. Chem., 2010, 18, 8418-8456.
29. Matsoukas, J.M.; Hondrelis, J.; Keramida, M.; Mavromoustakos, T.; Makriyannis, A.; Yamdagni, R.; Wu, Q.; Moore, G.J. Role of the NH2-terminal domain of angiotensin II (ANG II) and [Sar1]angiotensin II on conformation and activity. NMR evidence for aromatic ring clustering and peptide backbone folding compared with [des-1,2,3]angiotensin II. J. Biol. Chem., 1994, 269, 5303-5312.
30. Mavromoustakos, T.; Kolocouris, A.; Zervou, M.; Roumelioti, P.; Matsoukas, J.; Weisemann, R. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. J. Med. Chem., 1999, 42, 1714-1722.
31. Dandona, P.; Dhindsa, S.; Ghanim, H.; Chaudhuri, A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J.Hum. Hypertens., 2007, 21, 20-27.
32. Kobori, H.; Prieto-Carrasquero, M.C.; Ozawa, Y.; Navar, L.G. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension, 2004, 43, 1126-1132.
33. Qaradakhi, T.; Apostolopoulos, V.; Zulli, A. Angiotensin (1-7) and Alamandine: Similarities and differences. Pharmacol. Res., 2016, 111, 820-826.
34. Qaradakhi, T.; Matsoukas, M.T.; Hayes, A.; Rybalka, E.; Caprnda, M.; Rimarova, K.; Sepsi, M.; Busselberg, D.; Kruzliak, P.; Matsoukas, J.; Apostolopoulos, V.; Zulli, A. Alamandine reverses hyperhomocysteinemia-induced vascular dysfunction via PKAdependent mechanisms. Cardiovasc. Ther., 2017, 35, e12306.
35. Habiyakare, B.; Alsaadon, H.; Mathai, M.L.; Hayes, A.; Zulli, A. Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7). Int. J. Exp. Pathol., 2014, 95, 290-295.
36. Lautner, R.Q.; Villela, D.C.; Fraga-Silva, R.A.; Silva, N.; Verano-Braga, T.; Costa-Fraga, F.; Jankowski, J.; Jankowski, V.; Sousa, F.; Alzamora, A.; Soares, E.; Barbosa, C.; Kjeldsen, F.; Oliveira, A.; Braga, J.; Savergnini, S.; Maia, G.; Peluso, A.B.; Passos-Silva, D.; Ferreira, A.; Alves, F.; Martins, A.; Raizada, M.; Paula, R.; Motta-Santos, D.; Klempin, F.; Pimenta, A.; Alenina, N.; Sinisterra, R.; Bader, M.; Campagnole-Santos, M.J.; Santos, R.A. Discovery and characterization of alamandine: a novel component of the reninangiotensin system. Circulation Res., 2013, 112, 1104-1111.
37. Villela, D.C.; Passos-Silva, D.G.; Santos, R.A. Alamandine: a new member of the angiotensin family. Curr. Opinion Nephrol. Hypertens., 2014, 23, 130-134.
38. Matsoukas, M.T.; Potamitis, C.; Plotas, P.; Androutsou, M.E.; Agelis, G.; Matsoukas, J.; Zoumpoulakis, P. Insights into AT1 receptor activation through AngII binding studies. J. Chem. Inform. Model., 2013, 53, 2798-2811.
39. Manoranjani, M.; Bhagyakumar, T. RP-HPLC method for the estimation of Valsartan in pharmaceutical dosage forms. Int. J. Sci. Inn. Dis., 2011, 1, 101-108.
40. Ravichandran, V.; Shalini, S.; Sundram, K.; Harish, R. Validation of analytical methods-strategies & importance. Int. J. Pharmac. Sci. 2010, 2, 18-22.
41. Gikas, E.; Bazoti, F.; Fanourgiakis, P.; Perivolioti, E.; Roussidis, A.; Skoutelis, A.; Tsarbopoulos, A. Development and validation of UPLC-UV method for the determination of daptomycin in rabbit plasma. Bio. Chrom., 2009, 24, 522-527.
42. Bazoti, F.N.; Gikas, E.; Skoutelis, A.; Tsarbopoulos, A. Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma. J. Pharm. Biomed. Analysis, 2011, 56, 78-85.
43. Abdul, A.; Mohammed, A.; Kanchan, K.; Yasmin, S.; Mohd, M.; Asgar, A. Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action. Drug Dev. Ind. Phar., 2011, 37, 583-596.
44. Babu, D.; Sagar, K.; Bhoot, M.; Swaroop, A.; Rao, N. Design and Evaluation of Valsartan Transdermal Patches. Int. J. Res. Ayur. Phar., 2012, 3.
45. Zulli, A.; Hare, D.L.; Buxton, B.F.; Widdop, R.E. Vasoactive role for angiotensin II type 2 receptors in human radial artery. Int. J. Immunopathol. Pharmacol., 2014, 27, 79-85.
46. Zulli, A.; Ye, B.; Wookey, P.J.; Buxton, B.F.; Hare, D.L. Calcitonin gene-related peptide inhibits angiotensin II-mediated vasoconstriction in human radial arteries: role of the Kir channel. J. Thorac. Cardiovasc. Surg., 2008, 136, 370-375.
47. Alsaadon, H.; Kruzliak, P.; Smardencas, A.; Hayes, A.; Bader, M.; Angus, P.; Herath, C.; Zulli, A. Increased aortic intimal proliferation due to MasR deletion in vitro. Int. J. Exper. Pathol., 2015, 96, 183-187.
48. Jones, E.S.; Black, M.J.; Widdop, R.E. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J. Mol. Cell. Cardiol., 2004, 37, 1023-1030.
49. Li, X.C.; Widdop, R.E. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br. Pharmacol., 2004, 142, 821-830.
50. Campbell, S.; Alexander-Lindo, R.; Dasgupta, T.; McGrowder, D. The effect of S-nitrosocaptopril and S-nitroso-N-acetyl-D.Lpenicillamine on blood glucose concentration and haemodynamic parameters. J. App. Biomed., 2009, 7, 123-131.
51. Benson, H.A. Transdermal drug delivery: penetration enhancement techniques. Curr. Drug Deliv., 2005, 2, 23-33.
52. Kielhorn, J.; Melching, S.; Mangelsdorf, I. Dermal Absorption World Health Organization, Germany, 2006, 17-18, 56-57.
53. Vikas, S.; Seema, S.; Gurpreet, S.; Rana, A.; Baibhav, J. Penetration enhancers: A novel strategy for enhancing transdermal drug delivery. Int. Res. J. Pharm., 2011, 2, 32-36.
54. Kumar, R.; Philip, A. Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop. J. Pharm., 2007, 6, 633-644.
55. Baviskar, D.T.; Parik, V.B.; Gupta, H.N.; Maniyar, A.H.; Jain, D.K. Design and evaluation of patches for transdermal delivery of losartan potassium. PDA J. Pharma. Sci. Technol., 2012, 66, 126-135.
56. Thakur, R.; Anwer, M.K.; Shams, M.S.; Ali, A.; Khar, R.K.; Shakeel, F.; Taha, E.I. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. J. Drug Targeting, 2009, 17, 442-449.
57. Pisipati, A.; Kalva, B.; Chavali, V.; Satya, S. Design and Evaluation of Transdermal Delivery System Containing Losartan Potassium. J. Pharm. Res., 2012, 5, 4443-4448.
58. Furchgott, R.F. Role of endothelium in responses of vascular smooth muscle. Circ. Res., 1983, 53, 557-573.
59. Loria, A.S.; Kang, K.T.; Pollock, D.M.; Pollock, J.S. Early life stress enhances angiotensin II-mediated vasoconstriction by reduced endothelial nitric oxide buffering capacity. Hypertension, 2011, 58, 619-626.
60. Wakabayashi, I.; Sakamoto, K.; Hatake, K.; Yoshimoto, S.; Kurahashi, M. Effect of age on contractile response to angiotensin II in rat aorta. Life Sci., 1990, 47, 771-779.
61. Matsoukas, J.M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos, D.; Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H.L.; Ganter, R.; Moore, G. Differences in backbone structure between angiotensin II agonists and type I antagonists. J. Med. Chem., 1995, 38, 4660-4669.
62. Polevaya, L.; Mavromoustakos, T.; Zoumboulakis, P.; Golic Grdadolnik, S.; Roumelioti, P.; Giatas, N.; Mutule, I.; Keivish, T.; Vlahakos, D.V.; Iliodromitis, E.K.; Kremastinos, D.T.; Matsoukas, J. Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists. Bioorg. Med. Chem., 2001, 9, 1639-1647.